[Clinical profile of acemetacin].
Explore the source record for details and available documents.
Anti-Inflammatory Agents, Non-Steroidal↗
Biomedical subjects
H Rechziegler
Publications and source records attributed to H Rechziegler.
Acemetacin in the treatment of rheumatic diseases: an open, multi-centre trial.
An open, multi-centre trial was carried out to assess the efficacy and tolerance of acemetacin in the treatment of patients suffering from various rheumatic diseases. The patients were treated by general practitioners for a maximum period of 6 weeks with a daily dose of 60 mg acemetacin 3-times daily. Assessments were made before, during and after treatment of pain parameters, joint function and swelling, and records kept of any adverse events reported. At the end of treatment, the physician made an overall assessment of response. Data from 760 patients were analyzed and showed 'very good' or 'good' improvement in 55% and 28.5% of patients, respectively. A relatively low percentage (16.3%) reported adverse events, which may or may not have been drug related, and there were few reports (10.7%) of gastric complaints. Twenty-seven (3.6%) patients withdrew from the study for reasons not specified.
Adult↗
[Non-steroid antirheumatic agents. Criteria for a rational selection].
It becomes more and more difficult for the physician to inform himself, because the number of nonsteroidal antiinflammatory drugs will arise. Therefore some preponderant clinical parameters should be taken into mind as basis of a rational treatment before prescribing a special NSAID. With regard to pharmacological action and therapeutic efficacy there are mentioned strength of antiinflammatory action, corticosteroid sparing effect, protein binding and drug levels in inflamed tissue. Assessment of tolerance should include inhibition of prostaglandin synthesis, occult gastrointestinal blood loss, half-life, route of renal elimination, drug interactions, DNA-repair and DNA-synthesis. Drugs on which published results concerning these parameters are available should be preferably prescribed.
Anti-Inflammatory Agents↗
[Multicentre long-term study with acemetacin (author's transl)].
Explore the source record for details and available documents.
Adult↗
[Interactions of non-steroidal antirheumatic drugs with oral antidiabetic agents: acemetacin--glibenclamide].
In a double-blind cross-over trial on 20 diabetic patients of type IIb we investigated whether a drug interaction between glibenclamide and acemetacin may possibly occur. After hospitalization of all in-patients needing glibenclamide therapy, a one-week period of adaptation to clinical conditions with optimized diet, antidiabetic dosage of the drug and the beginning of a diabetes learning programme followed. Thereafter, in a randomized design, ten out of the 20 patients were treated concomitantly with either 60 mg acemetacin t.i.d. or placebo for 1 week. Furthermore, a cross-over period of one week's duration followed once more. Daily blood glucose profiles (four values) were measured every second day and suggested a continuous improvement of the severe diabetic state previously seen. Blood glucose levels reached an optimal steady-state condition after 1 week of adaptation. Concomitant treatment with acemetacin did not lead to a relevant alteration of the laboratory parameters used in type IIb diabetic patients. This could also be established due to HbA1 values. Contrary to other nonsteroidal anti-inflammatory drugs, interactions between acemetacin and the widely used oral antidiabetic glibenclamide could not be established.
Anti-Inflammatory Agents, Non-Steroidal↗